← Back to Search
Risk Factors For Brain Relapse In Patients With Metastatic Breast Cancer.
K. Slimane, F. André, S. Delaloge, A. Dunant, A. Perez, J. Grenier, C. Massard, M. Spielmann
Published 2004 · Medicine
Download PDFAnalyze on Scholarcy
BACKGROUND The occurrence of brain metastases is an emerging problem in patients with metastatic breast cancer. In the present study, we looked at risk factors for brain metastasis among patients with metastatic breast cancer. PATIENTS AND METHODS The risk factors for brain metastasis were first determined in a series of 215 patients with metastatic breast cancer. Risk factors identified in the multivariate analysis were re-evaluated in a confirmatory series of 199 patients with metastatic breast cancer. All the patients had been included in prospective randomized trials that evaluated chemotherapy or endocrine therapy in an adjuvant setting. RESULTS In the first series, the presence of lung metastases (hazard ratio = 4.3, 95% CI: 1.9-9.3, P=0.0003) and negative hormone receptor status (hazard ratio = 4.2, 95% CI: 1.7-11, P=0.002) were the only predictive factors associated with the occurrence of brain metastases in the multivariate analysis. The second series confirmed that the presence of lung metastases and negative hormone receptor status were associated with the occurrence of brain metastases. CONCLUSION The presence of lung metastases as the first site of relapse and a negative hormone receptor status are predictive for the occurrence of brain metastases in patients with metastatic breast cancer. A prophylactic treatment should be evaluated in these subsets of patients.
This paper references
High incidence of central nervous system involvement in patients with breast cancer treated with epirubicin and docetaxel.
H. Abali (2002)
Oestrogen receptors, sites of metastatic disease and survival in recurrent breast cancer.
J. Stewart (1981)
Prophylactic cranial irradiation in locally advanced non-small-cell lung cancer after multimodality treatment: long-term follow-up and investigations of late neuropsychologic effects.
M. Stuschke (1999)
Survival of patients with metastatic breast carcinoma
J. Chang (2003)
Pharmacokinetics and toxicity of high-dose intravenous methotrexate in the treatment of leptomeningeal carcinomatosis
M. Tetef (2000)
High incidence of central nervous system involvement in patients with metastatic or locally advanced breast cancer treated with epirubicin and docetaxel.
D. Crivellari (2001)
Involvement of chemokine receptors in breast cancer metastasis
A. Müller (2001)
CXCR4 Regulates Interneuron Migration in the Developing Neocortex
R. Stumm (2003)
Randomized trial of adjuvant ovarian suppression in 926 premenopausal patients with early breast cancer treated with adjuvant chemotherapy.
R. Arriagada (2005)
The seed and soil hypothesis: vascularisation and brain metastases.
I. Fidler (2002)
Expression pattern of CXC chemokine receptor-4 is correlated with lymph node metastasis in human invasive ductal carcinoma
M. Kato (2003)
CNS-directed therapy for childhood acute lymphoblastic leukemia: Childhood ALL Collaborative Group overview of 43 randomized trials.
M. Clarke (2003)
Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels.
M. Colleoni (2002)
Chemokine receptor CXCR4 and early-stage non-small cell lung cancer: pattern of expression and correlation with outcome.
J. Spano (2004)
Determinants and prognoses of locoregional and distant progression in breast cancer.
J. Engel (2003)
Patterns of failure in a randomized trial of adjuvant chemotherapy in postmenopausal patients with early breast cancer treated with tamoxifen.
R. Arriagada (2002)
Central nervous system metastases in women who receive trastuzumab‐based therapy for metastatic breast carcinoma
J. Bendell (2003)
Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group.
A. Aupérin (1999)
Occult central nervous system involvement in patients with metastatic breast cancer: prevalence, predictive factors and impact on overall survival.
K. Miller (2003)
Role of elective brain irradiation during combined chemoradiotherapy for limited disease non-small cell lung cancer
T. Umsawasdi (2004)
Patterns of failure in two randomized trials of adjuvant anthracycline-based chemotherapy in 1,146 patients with early breast cancer
T Tursz (2003)
Estrogen receptor: a prognostic factor in breast cancer.
N. Samaan (1981)
This paper is referenced by
A systematic review of trastuzumab and lapatinib in the treatment of women with brain metastases from HER2-positive breast cancer.
P. B. Larsen (2013)
[Brain metastases epidemiology and biology].
E. Tabouret (2013)
New challenges and opportunities in the management of brain metastases in patients with ErbB2-positive metastatic breast cancer
M. Melisko (2009)
Genes that mediate breast cancer metastasis to the brain
P. Bos (2009)
Neuroimaging of parenchymal brain metastases.
M. Walker (2007)
Chemotherapy in breast cancer patients with brain metastases: have new chemotherapic agents changed the clinical outcome?
A. Tosoni (2008)
The Basal Phenotype of BRCA1-Related Breast Cancer: Past, Present and Future
M. Tischkowitz (2006)
Contemporary Review of the Management of Brain Metastasis with Radiation
D. Khuntia (2015)
Effect of lapatinib on the outgrowth of metastatic breast cancer cells to the brain.
B. Gril (2008)
Carcinomatous meningitis as first sign of relapse in a patient with gastric Adenocarcinoma: A rare presentation
Akash Mathur (2017)
Triple-negative and HER2-overexpressing breast cancers exhibit an elevated risk and an earlier occurrence of cerebral metastases.
F. Heitz (2009)
Review Article Leptomeningeal metastases in breast cancer
B. J. Scott (2013)
Risk factors for central nervous system metastasis in patients with metastatic breast cancer
C. Sezgin (2007)
Central nervous system metastases in HER-2 positive metastatic breast cancer patients treated with trastuzumab: incidence, survival, and risk factors.
S. Gori (2007)
Treatment of brain metastases in the modern genomic era
I. Dagogo-Jack (2017)
Lapatinib plus capecitabine resolved human epidermal growth factor receptor 2-positive brain metastases.
Stefan Glück (2009)
Management of neurological complications in metastatic breast cancer
W. Bouwknegt (2006)
Factors influencing the time to development of brain metastases in breast cancer.
S. Fromm (2008)
When Standard Therapy Fails in Breast Cancer: Current and Future Options for HER2-Positive Disease
E. Olson (2013)
Role of HER2 status in the treatment for brain metastases arising from breast cancer with stereotactic radiosurgery
M. Tam (2014)
Multifactorial central nervous system recurrence susceptibility in patients with HER2‐positive breast cancer
A. Musolino (2011)
Stereotactic radiosurgery for four or more intracranial metastases.
A. Bhatnagar (2006)
Distant disease-free interval, site of first relapse and post-relapse survival in BRCA1- and BRCA2-associated compared to sporadic breast cancer patients
M. Kriege (2007)
Retrospective analysis of metastatic behaviour of breast cancer subtypes
C. D. Savci-Heijink (2015)
Current Therapeutic Options for Breast Cancer Central Nervous System Metastases
M. B. Hemphill (2008)
Central nervous system relapse in patients with breast cancer is associated with advanced stages, with the presence of circulating occult tumor cells and with the HER2/neu status
J. Souglakos (2006)
Risk factors for the development of brain metastases in patients with HER2-positive breast cancer
C. Maurer (2018)
Determining Risk Factors for Local Recurrence and Metastasis in Breast Cancer Patients Using Bivariate Logistic Model
S. Hossein-Zadeh (2016)
Métastases cérébrales dans les cancers du sein. Épidémiologie et histoire naturelle. Expérience de l’Institut Curie à travers deux études : les patientes HER2- de moins de 65 ans et les patientes de plus de 65 ans.
J. Gachet (2011)
Brain metastases of breast cancer.
D. Palmieri (2006)
Spectrum of breast cancer metastasis in BRCA1 mutation carriers: highly increased incidence of brain metastases.
L. Albigès (2005)
Experimental modeling and novel therapeutic strategies in melanoma brain metastasis
Terje Sundstrøm (2015)See more